Stockscreener 앱 받기
6.34
0.96%
0.06
시간 외 거래:
6.34
전일 마감가:
$6.28
열려 있는:
$6.3
하루 거래량:
35,521
Relative Volume:
0.26
시가총액:
$189.75M
수익:
$31.37M
순이익/손실:
$-53.77M
주가수익비율:
-4.3613
EPS:
-1.4537
순현금흐름:
$-49.02M
1주 성능:
+4.97%
1개월 성능:
+9.31%
6개월 성능:
+11.42%
1년 성능:
-69.84%
1일 변동 폭
$6.20
$6.48
1주일 범위
$5.7554
$6.48
52주 변동 폭
$1.97
$21.99
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
명칭
Silence Therapeutics Plc Adr
전화
44-0-20-3457 6900
주소
72 HAMMERSMITH ROAD, LONDON
SLN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
6.34 | 296.61M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 개시 | Goldman | Sell |
| 2024-12-02 | 재확인 | BMO Capital Markets | Outperform |
| 2024-09-03 | 개시 | Jefferies | Buy |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr 주식(SLN)의 최신 뉴스
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade - Yahoo.co
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus - Zacks Investment Research
Silence Therapeutics soars 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
H.C. Wainwright reiterates buy rating on Silence Therapeutics stock By Investing.com - Investing.com South Africa
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - MSN
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year By Investing.com - Investing.com India
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics stock hits 52-week low at $3.19 By Investing.com - Investing.com South Africa
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - MSN
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn - Investing.com
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn By Investing.com - Investing.com South Africa
Taiwan Semiconductor Valuation: How Realistic Is the Price? - The Globe and Mail
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges - Investing.com
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Goldman Sachs cuts Silence Therapeutics stock rating to Sell By Investing.com - Investing.com South Africa
Should investors be concerned about Silence Therapeutics Plc ADR (SLN)? - US Post News
Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex
Cloudflare Inc’s (NET) Stock: A 29.10% Simple Moving Average for the Past 20 Days - The News Heater
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges - Investing.com
H.C. WAINWRIGHT MAINTAINS $75 TARGET ON SILENCE THERAPEUTICS STOCK By Investing.com - Investing.com South Africa
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Nasdaq
Silence Therapeutics weakness after AHA updates ‘overdone,’ says BMO Capital - Nasdaq
Zerlasiran shows promise in phase 2 study for cardiovascular risk - Investing.com India
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Silence Therapeutics to Join Guggenheim Biotech Conference By Investing.com - Investing.com India
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - Nasdaq
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? - Nasdaq
Claire Keast-Butler - Cooley
Our approach to nucleotide-based therapeutics - AstraZeneca
5 Stocks to Buy as the Drug Industry Bets Big on Innovation - Nasdaq
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Genfit (NASDAQ:GNFT) Stock Quotes, Forecast and News Summary - Benzinga
SLN News Today | Why did Silence Therapeutics stock go down today? - MarketBeat
Silence Therapeutics (SLN) Stock Price, News & Analysis - MarketBeat
Silence Therapeutics (SLN) - Zacks Investment Research
Silence Therapeutics Plc Adr (SLN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):